Loading…
GlaxoSmithKline Pharmaceuticals (GLAXO)₹2,710+6.71%Pharmaceuticals
At the end of the Jun 2026 quarter, GlaxoSmithKline Pharmaceuticals' shareholders were: promoters 74.95%, FIIs 4.78%, DIIs 7.86%, public 12.41%. Promoter holding is unchanged on the quarter. FII holding is down 0.10 percentage points from 4.88% a year earlier. 0.00% of promoter shares were pledged. It had 1,26,137 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 74.95% | 74.95% | 74.95% | 74.95% | 74.95% | 74.95% | 74.95% | 74.95% | 74.95% | 74.95% | 74.95% | 74.95% |
| FIIs | 2.49% | 2.92% | 3.47% | 4.01% | 4.35% | 4.49% | 4.51% | 4.88% | 4.78% | 4.62% | 4.61% | 4.78% |
| DIIs | 10.06% | 8.69% | 7.95% | 7.56% | 7.39% | 7.35% | 7.84% | 7.76% | 7.80% | 7.75% | 7.73% | 7.86% |
| Government | 0.01% | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 12.49% | 13.43% | 13.63% | 13.48% | 13.31% | 13.21% | 12.70% | 12.41% | 12.47% | 12.68% | 12.71% | 12.41% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 1,15,314 | 1,14,709 | 1,19,041 | 1,18,562 | 1,19,276 | 1,19,673 | 1,21,934 | 1,23,678 | 1,22,953 | 1,22,509 | 1,21,812 | 1,26,137 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Glaxo Group Limited | Promoter | 36.02% | 0.00 |
| Glaxosmithkline Pte Limited | Promoter | 28.14% | 0.00 |
| Eskaylab Limited | Promoter | 6.90% | 0.00 |
| Burroughs Wellcome International Limited | Promoter | 3.96% | 0.00 |
| Lici Asm Non Par | DII | 1.07% | 0.00 |
Promoters held 74.95% of GlaxoSmithKline Pharmaceuticals at the end of the Jun 2026 quarter, the same as a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 4.78% (up 0.17 percentage points from 4.61% a quarter earlier) and domestic institutions (DIIs) held 7.86% (up 0.13 percentage points from 7.73% a quarter earlier).
No. The Jun 2026 filing shows no pledged promoter shares.
GlaxoSmithKline Pharmaceuticals had 1,26,137 shareholders at the end of the Jun 2026 quarter, against 1,23,678 a year earlier.
Lici Asm Non Par (DII) held 1.07% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.